A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland
Michaela Carla Barbier, Esther Pardo, Cédric Michael Panje, Oliver Gautschi, Judith Eva Lupatsch for the Swiss Group for Clinical Cancer Research (SAKK)
Year of publication: |
2021
|
---|---|
Authors: | Barbier, Michaela Carla ; Pardo, Esther ; Panje, Cédric Michael ; Gautschi, Oliver ; Lupatsch, Judith Eva |
Published in: |
The European journal of health economics. - Berlin : Springer, ISSN 1618-7601, ZDB-ID 2011428-X. - Vol. 22.2021, 5, p. 669-677
|
Subject: | Non-small cell lung cancer | Pembrolizumab | Cost-effectiveness | Markov model | Krebskrankheit | Cancer | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Schweiz | Switzerland | Gesundheitsökonomik | Health economics | Gesundheitskosten | Health care costs |
Saved in:
freely available
Saved in favorites
Similar items by subject
-
Nguyen Cuc Thi Thu, (2019)
-
Schwander, Bjoern, (2014)
-
Jin, Huajie, (2019)
- More ...